Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00888329 · ClinicalTrials.gov registry record · Phase 4
Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy
A Phase 4 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 4
- Development phase
- 256
- Enrollment target
NCT00888329: Clinical Trial Phase 4 study, sponsored by Mayo Clinic.
NCT00888329 is a Phase 4 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 256 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (51% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00888329, a Phase 4 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 256 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether 40 mg aprepitant administered before surgery is effective for preventing vomiting in the first 24 hours after surgery in women undergoing elective hysterectomy.
Primary Outcome
This is the number of participants who had an episode of vomiting within 24 hours after emergence from anesthesia.
Interventions
- DRUG Placebo
- DRUG Aprepitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-10 |
| Phase | Phase 4 |
Why NCT00888329 stopped before completion
NCT00888329 is an interventional study that assigns participants to a tested intervention. The registered 256 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (51% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00888329 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00888329 about?
NCT00888329 is a clinical study titled "Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy". The purpose of the study is to determine whether 40 mg aprepitant administered before surgery is effective for preventing vomiting in the first 24 hours after surgery in women undergoing elective hysterectomy.
What is the current status of trial NCT00888329?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 256 participants. The study started on 2007-07. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00888329?
The interventions under investigation include: Placebo (DRUG), Aprepitant (DRUG).
Who is sponsoring clinical trial NCT00888329?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00888329's enrollment target sits among peer trials
256 332nd of 2000 higher than 1,667 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02464696 · 256 participants · NA
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
- NCT03793062 · 256 participants
Genetic and Epigenetic Basis of Chronic Wounds
- NCT04322318 · 256 participants · Phase 2
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- NCT04468360 · 256 participants · Phase 2
Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia